Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 94.4% in September

Vor Biopharma Inc. (NASDAQ:VOR) saw a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 1,100,000 shares, a decline of 94.4% from the August 31st total of 19,780,000 shares. Approximately 27.9% of the shares of the stock are sold short. Based on an average daily volume of 909,000 shares, the short-interest ratio is presently 1.2 days. Based on an average daily volume of 909,000 shares, the short-interest ratio is presently 1.2 days. Approximately 27.9% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. HC Wainwright raised shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 30th. Zacks Research raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 10th. Finally, Wall Street Zen lowered Vor Biopharma to a “strong sell” rating in a research note on Saturday, June 28th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Vor Biopharma presently has an average rating of “Buy”.

Vor Biopharma Stock Performance

Vor Biopharma stock opened at $39.26 on Thursday. Vor Biopharma has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The stock has a 50 day moving average price of $39.14. The stock has a market capitalization of $268.93 million, a P/E ratio of -0.14 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.